Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may translate into big problems for Johnson & Johnson, Merck, and other ...
Critics, including some drugmakers, argue that new patent policies would make it more difficult for companies to bring ...
Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...
Zacks Investment Research on MSN
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
TipRanks on MSN
Novavax price target lowered to $16 from $18 at B. Riley
B. Riley lowered the firm’s price target on Novavax (NVAX) to $16 from $18 and keeps a Buy rating on the shares following the Q3 report. The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback